Global Rheumatoid Arthritis Therapeutics Market Report and Forecast 2024-2032

Global Rheumatoid Arthritis Therapeutics Market Report and Forecast 2024-2032


Rheumatoid Arthritis Therapeutics Market Report and Forecast 2024-2032

Rheumatoid Arthritis Therapeutics Market Size

The rheumatoid arthritis therapeutics market was valued at USD 29506.4 million in 2023, driven by the increasing prevalence of rheumatoid arthritis across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2024-2032, with the values likely to rise from USD 30.864 billion in 2024 to USD 44228.4 million by 2032.

Rheumatoid Arthritis Therapeutics Market Outlook
  • A significant driver of the market is the increasing prevalence of rheumatoid arthritis and the growing aging population.
  • One of the major market trends is the surge in clinical trials of new and advanced rheumatoid arthritis medications which are anticipated to enhance patient outcomes and stimulate market expansion.
  • There is a growing market demand for biologics due to their ability to target specific parts of the immune system responsible for inflammation and prevent long-term disability associated with rheumatoid arthritis.
Rheumatoid Arthritis Therapeutics Market Overview

Rheumatoid arthritis (RA) is an auto-immune disorder, a condition in which a person's immune system identifies one's cellular and organ makeup as antigenic entities, resulting in the synthesis of antibodies against one's own body. The disease tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain. If left untreated, the disease could spread across various organs, which initially affect the joints of fingers and toes. A surge in obesity rates, increasing awareness concerning rheumatic disorders, and the rising geriatric population have significantly contributed to the market growth. Additionally, the rise in generic drug approvals and growth in clinical trials reflects the ongoing expansion of the market.

Rheumatoid Arthritis Therapeutics Market Growth Drivers

Growing Prevalence of Rheumatoid Arthritis Drives the Market Demand

A significant driver in the market includes the growing prevalence of the disease. Recent data reveals that around 1.5 million people in the United States are affected by rheumatoid arthritis. Moreover, females are reported to be nearly three times more likely to develop the autoimmune condition as compared to males. Research has shown that early treatment can put the disease into remission , reflecting the importance of effective therapeutics to manage the condition. Thus, with the rising cases of the disease, the market demand for these drugs is expected to witness a rise. Further, the increasing aging population which is at a higher risk of developing the disorder is poised to influence the market landscape.

Rheumatoid Arthritis Therapeutics Market Trends

Rising Entry of Generic Drugs Supports the Market Expansion

In August 2023 , an Indian multinational pharmaceutical company Zydus Lifesciences Limited received the United States US Food and Drug Administration's (FDA) approval to manufacture and market its generic Indomethacin suppositories (50 mg strength), a non-steroidal and anti-inflammatory drug used for the treatment of moderate to severe rheumatoid arthritis. The FDA also granted a 180-day competitive generic therapy (CGT) exclusivity to market the generic treatment drug as it deemed there is inadequate generic competition for the drug in the United States market. The rise in the approval of generic therapeutics indicated for rheumatoid arthritis is likely to improve the accessibility of treatment alternatives to the growing patient pool, which is projected to bolster the market growth in the forecast period.

Surge in Clinical Trials of Novel Therapies to Meet the Rising Rheumatoid Arthritis Therapeutics Market Demand

One of the major market trends is the growth in clinical trials of new and advanced rheumatoid arthritis medications which are anticipated to enhance patient outcomes and stimulate market expansion. In October 2023 , a United States-based biotechnology company Rise Therapeutics revealed that the regulatory agency FDA has accepted its investigational new drug (IND) application that will allow initiation of the Phase I clinical trial of R-2487 intended for the treatment of rheumatoid arthritis. In the single and repeat-dose clinical study enrolling 36 subjects, the cellular immunotherapy R-2487 will be assessed for tolerability, drug exposure, safety, and clinical activity. It is reported that the clinical activity of R-2487 will be evaluated by measuring improvement in rheumatoid arthritis disease severity and other biomarkers. The development of such oral immunotherapy treatments that can facilitate ease of delivery of protein-based biologics therapy and are available at reduced costs are projected to positively impact the market dynamics.

Rising Preference for Combination Therapies is Projected to Boost Rheumatoid Arthritis Therapeutics Market Size

Treatments for rheumatoid arthritis manage inflammation in the affected patients and can ease associated symptoms like pain and stiffness. However, sometimes a single drug is not sufficient to treat this autoimmune disease. In such cases, patients are prescribed with more than one drug to effectively control the symptoms. For example, a treatment that combines ethotrexate with leflunomide or methotrexate with sulfasalazine is reported to be the most effective two-drug combinations of conventional disease-modifying antirheumatic drugs (DMARDs) . The rising demand for combination therapies due to their ability to provide better clinical benefits is anticipated to fuel the market size.

Advances in Personalized Medicine is Likely to Elevate Rheumatoid Arthritis Therapeutics Market Value

The rising advancements in personalized treatment approaches supported by robust research initiatives is resulting in tailored therapies that can improve patient outcomes. Biomarkers are increasingly employed as key tools in the development of personalized medicine towards rheumatoid arthritis to accurately predict the patient’s disease phenotype and response to treatment. Further, the growing innovation in omic technologies and clinical study design is expected to accelerate rheumatoid biomarker discovery, which is likely to amplify the demand for precision medicine, thereby stimulating market growth.

Rheumatoid Arthritis Therapeutics Market Segmentation

Market Breakup by Product Type
  • Biologics
  • Non-Biologics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
  • Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
  • Others
Market Breakup by Sales Type
  • Prescription
  • Over The Counter (OTC)
  • Others
Market Breakup by Route of Administration
  • Oral
  • Parenteral
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
Market Breakup by End User
  • Hospitals & Clinics
  • Research and Academic Laboratories
  • Others
Market Breakup by Region
  • United States
  • EU-4 and United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India
Rheumatoid Arthritis Therapeutics Market Share

Market Segmentation Based on Product Type is Poised to Propel Market Growth

The market segmentation by product type includes biologics and non-biologics. Biologics include advanced drugs such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors. These medications target specific parts of the immune system responsible for inflammation in rheumatoid arthritis. Non-biologics are further subdivided into non-steroidal anti-inflammatory drugs (NSAIDs), synthetic disease-modifying antirheumatic drugs (SDMARDs) like methotrexate, and other medications including corticosteroids that help manage symptoms or certain complications. There is a growing demand for biologics due to their ability to prevent long-term disability associated with the disease is likely to augment the rheumatoid arthritis therapeutics market demand.

Prescription and Over-the-Counter Rheumatoid Arthritis Therapeutics are Witnessing Market Demand

Based on the sales type, the market comprises prescription, and over-the-counter rheumatoid arthritis therapeutics, among others. Prescription drugs hold a significant share, including majority of rheumatoid arthritis therapies that require medical oversight due to their potential side effects. Over-the-counter (OTC) drugs, mainly some non-steroidal anti-inflammatory (NSAIDs), are available without a prescription to manage pain and inflammation. Advil and Aleve are some examples of widely used rheumatoid arthritis drugs that are sold over-the-counter.

Rheumatoid Arthritis Therapeutics Market Analysis by Region

The market is witnessing colossal growth in United States due to the highest reported disease cases. Moreover, the increasing awareness and health consciousness among people have significantly contributed to the dominant share of the regional market. Also, the increasing budget allocation in the arena of rheumatoid arthritis therapeutics equally raises its market value.

EU-4 and the United Kingdom has seen significant propellants in the form of innovative drugs, advanced healthcare alternatives to grapple with the disease, and an increment in cases. In the Asia Pacific region, Japan, and India’s market growth is catalyzed by the improvement in healthcare infrastructure, increasing awareness, and growing adoption of biologics.

Leading Players in the Rheumatoid Arthritis Therapeutics Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • UCB S.A.
  • Gilead Sciences, Inc.
  • Boehringer Ingelheim GmbH
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie
  • Eli Lilly and Company
  • Celgene Corporation
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in the Rheumatoid Arthritis Therapeutics Market Report
  • What was the rheumatoid arthritis therapeutics market value in 2023?
  • What is the rheumatoid arthritis therapeutics market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on product type?
  • What is the market breakup based on sales type?
  • What is the market breakup by route of administration?
  • What are the various distribution channels present in the market?
  • What are the major end users in the market?
  • What are the major factors aiding the rheumatoid arthritis therapeutics market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • How does the prevalence and incidence of rheumatoid arthritis affect the market landscape?
  • What are the major rheumatoid arthritis therapeutics market trends?
  • How does the rise in the geriatric population impact the market size?
  • Which product type will dominate the market share?
  • Which sales type is expected to have a high market value in the coming years?
  • Which route of administration will experience the highest demand in the market segment?
  • Which distribution channel is poised to cover a major market share?
  • Which end user is anticipated to drive market growth?
  • Who are the key players involved in the rheumatoid arthritis therapeutics market?
  • What clinical trials are undergoing in the market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
_____________________________________________________________________________

Meta description

The rheumatoid arthritis therapeutics market size was valued at USD 29506.4 million in 2023 and it is anticipated to grow at a CAGR of 4.60% during the forecast period of 2024-2032.*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Rheumatoid Arthritis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Rheumatoid Arthritis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Rheumatoid Arthritis Epidemiology (2016-2031)
5.3 Europe Rheumatoid Arthritis Epidemiology (2016-2031)
5.4 Asia-Pacific Rheumatoid Arthritis Epidemiology (2016-2031)
5.5 Latin America Rheumatoid Arthritis Epidemiology (2016-2031)
5.6 Middle East & Africa Rheumatoid Arthritis Epidemiology (2016-2031)
6 Global Rheumatoid Arthritis Therapeutics Market Overview
6.1 Global Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023)
6.2 Global Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
7 Global Rheumatoid Arthritis Therapeutics Market Landscape
7.1 Rheumatoid Arthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Rheumatoid Arthritis Therapeutics: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Rheumatoid Arthritis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Rheumatoid Arthritis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Rheumatoid Arthritis Therapeutics Market Segmentation
11.1 Global Rheumatoid Arthritis Therapeutics Market by Product Type
11.1.1 Market Overview
11.1.2 Biologics
11.1.3 Non-Biologics
11.1.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11.1.3.2 Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
11.1.3.3 Others
11.2 Global Rheumatoid Arthritis Therapeutics Market by Sales Type
11.2.1 Market Overview
11.2.2 Prescription
11.2.3 Over The Counter (OTC)
11.2.4 Others
11.3 Global Rheumatoid Arthritis Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.4 Global Rheumatoid Arthritis Therapeutics Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online
11.5 Global Rheumatoid Arthritis Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals & Clinics
11.5.3 Research and Academic Laboratories
11.5.4 Others
11.6 Global Rheumatoid Arthritis Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Rheumatoid Arthritis Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Rheumatoid Arthritis Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Rheumatoid Arthritis Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Rheumatoid Arthritis Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Rheumatoid Arthritis Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Amgen Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bristol-Myers Squibb Company
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 F. Hoffmann-La Roche Ltd
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 UCB S.A.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Gilead Sciences, Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Boehringer Ingelheim GmbH
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis International AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Regeneron Pharmaceuticals, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 AbbVie.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Rheumatoid Arthritis Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings